The rise of inversions may say as much about the lack of opportunities for growth that companies see as it does about the burdensome US tax code or the cleverness of investment bankers and accountants.
It may seem an odd question, but can financial engineering cure cancer? No less an intellectual light than Andrew W. Lo of MIT thinks financial engineering is a possibly potent weapon to aid in the ages old pursuit for a cancer cure.
Should asset allocation be adjusted in response to newly formed macroeconomic expectations, or should investors continue to use models based solely on past data and wait until a set time horizon expires?
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.